A new neurotrophic factor for Parkinson's disease
Parkinson's disease (PD) affects millions of people worldwide, and it is estimated that this number will have doubled by 2030 given the ageing demographic. Despite years of research, there is no therapy for PD. The EU-funded BMPARK project is investigating the potential of bone morphogenetic protein 2 (BMP2) as a neurotrophic factor to protect midbrain dopaminergic neurons in the brains of PD patients. Using a rat model of the disease, scientists will evaluate the efficacy of BMP2 in halting the progressive loss of dopaminergic neurons and improving motor function. The project's results will decipher the mode of BMP2 action and contribute to the future development of clinical strategies for PD.